Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of two long-term studies evaluating ambrisentan, an investigational endothelin receptor antagonist (ERA) for the treatment of patients with pulmonary arterial hypertension (PAH). These long-term data are from patients who originally participated in the two pivotal Phase III ARIES studies and AMB-222, a Phase II study of patients who had previously discontinued other ERAs because of liver function abnormalities. These studies were selected for oral presentation at ATS 2007, the International Conference of the American Thoracic Society, taking place in San Francisco, California, May 18-23.

"Pulmonary arterial hypertension is a progressive, life-threatening disease for which new therapies are clearly needed," said Ronald J. Oudiz, MD, Associate Professor of Medicine, UCLA School of Medicine and Director, Liu Center for Pulmonary Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. "The long-term clinical profile observed in these ambrisentan studies is very encouraging."

About the Studies

In the first presentation (Abstract #2307), Dr. Oudiz presented results from an integrated analysis of an ongoing, long-term extension study (ARIES-E) involving patients from the two 12-week Phase III placebo-controlled studies (ARIES-1 and ARIES-2). A total of 383 patients with idiopathic PAH or PAH associated with connective tissue disease, HIV infection, or anorexigen use who received at least one dose of ambrisentan (2.5, 5 or 10 mg once-daily) in ARIES-1, ARIES-2 or ARIES-E were included in the integrated analysis, which reflect data available as of February 2006 (mean exposure = 39 weeks; maximum exposure = 109 weeks).

Improvements in the non placebo-corrected 6-minute walk distance observed during the first 12 weeks of ambrisentan treatment (+37.7 meters) were sus
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/11/2014)... LOS ANGELES , July 11, 2014 /PRNewswire-iReach/ ... of e-liquid, a vegetable-glycol solution for use in ... one of the active ingredients in cannabis, cannabidiol ... in personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds ...
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
(Date:7/11/2014)... , July 11, 2014 The ... are evolving across industry sectors to better identify ... better ways to engage with and understand consumers, ... themselves and make critical purchasing decisions. ... Best Practices, LLC, one area where organizations can ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... Medical Tactile, Inc. and Valentus Medical Technologies, Inc. ... , Canada , has signed a partnership agreement with Medical Tactile, ... SureTouch™ , the non-invasive digital breast imaging technology, worldwide, with the ... , , ...
... July 13 Amira Pharmaceuticals, Inc. today announced that the ... Activating Protein (FLAP) Inhibitors," which includes coverage of Amira,s AM103 and ... , , ... , Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement ...
Cached Medicine Technology:Partnership Brings Breast Image Documentation Technology to Women Around the World 2Amira Announces AM103 and AM803 Patent Grant in the United Kingdom 2
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC has ... , Inc., a subsidiary of Johnson & Johnson, on behalf ... pain after receiving a metal-on-metal DePuy Pinnacle hip replacement and ... the artificial hip implant. The DePuy hip lawsuit was filed ... of Texas (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with ... questions. Paddock tackles topics including main men's health ... longer than men, and testosterone replacement therapy, among others. ... featured on Doylestown Hospital’s website, Dr. Brad Paddock says, ... If you notice pain, bulging, or asymmetry in your ...
(Date:7/12/2014)... 12, 2014 As reported in this ... Standards and Technology), the June 25th, 2014 Supreme Court ruling ... world. It was also met with both cheers ... whether it was seen from an individual privacy perspective, or ... fact, there is now precedent which will require law enforcement ...
(Date:7/12/2014)... Salt Lake City, Utah (PRWEB) July 12, 2014 ... Five spotlighted two types of startups, with awards being ... UVEF’s new emphasis spotlighted Utah’s outstanding entrepreneur community with ... are proving a sustainable model with incoming revenue. , ... companies from across the state that are under 5 ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... to a multitude of complications if left untreated. A ... of using tea as a form of treatment for ... to prevent the incidence of cataracts, a significant health ... ,Researchers developed special rats with diabetes. This provided ...
... Apollo Hospitals Group has been shortlisted by Britain's National Health ... UK where it could provide diagnostic services.// ,Long waiting ... of its operations to cut the delay faced by its ... radiology, including CT scan, MRIs, X-rays, endoscopy, ultra-sound and so ...
... stress during early life can lead to an increased ... It therefore, highlights the need for a counseling for ... growth. ,Several studies have established a relationship ... an increased risk of developing attachment disorders. These children ...
... at Harvard University, who say that these proteins and ... key to oncogenesis,// the process of formation of cancer ... protein known to cause cancer, is activated and becomes ... the hypothesis that an important component of oncogenesis is ...
... published in the Journal of the National Cancer Institute ... the link between diabetes and the prevalence and associated ... Susanna C. Larsson, M.Sc., of the Karolinska Institute in ... meant that individuals were at a 30 percent risk ...
... a very common disease of the present times; it is ... by way of incorporating specific foods has been found to ... clues for future diabetes treatment, following a doctor's advice on ... course of action and researchers are constantly on the lookout ...
Cached Medicine News:Health News:Apollo Hospitals Short-listed to Provide Diagnostics in the UK 2Health News:Teenage Mental Problems Could Be The Result Of Stress During Early Life 2Health News:Diet Effective In Curing Diabetes 2
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... Filters are ideal for ... methods, or for any ... might occur. They are ... solutions, infectious materials, labelled ...
Inquire...
Medicine Products: